1. Home
  2. Investors
  3. Press Releases

Press Releases

Nov 13, 2020
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed
Read more »
Oct 22, 2020
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on
Read more »
Sep 23, 2020
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory
Read more »
Sep 10, 2020
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
- Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy - Analysis of two placebo-controlled randomized trials shows nabiximols had no notable negative effects on cognition,
Read more »
Sep 10, 2020
Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
- Nearly one-third of survey respondents indicated use of THC-containing cannabis for Multiple Sclerosis (MS) symptom management CARLSBAD, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and
Read more »